glp-1 clinical studies Receptor Agonists as Treatments for Type 2 Diabetes GLP-1 therapies are powerful, but

But Novartis doesnt want to just be a me-too. Gal likens the situation with GLP-1s to whats happening in China, where a burst of innovation has led to concerns about the real gains being made there and whether many drugs are simply offering incremental improvements over existing options, particularly in oncology

This step is particularly important because prescribing medication across state lines can involve complex legal issues

A record of previous weight loss attemptsincluding diets, workout programs, or medications you've tried Challenges youve faced such as emotional eating, metabolic issues, or time constraints

Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME et al (2012) Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide